Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity

Latest Livdelzi Safety, Efficacy Data Presented at The Liver Meeting 2025

New interim safety and efficacy data for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar) demonstrates sustained itch relief and the potential to slow disease progression.

?Emerging Innovations in Hepatitis B Treatment Immunocores Promising Phase 1 Data on IMC-I109V?

'Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD's The Liver Meeting' In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle against hepatitis B. At the prestigious American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held recently, the biopharmaceutical company unveiled compelling Phase 1 clinical trial data for its promising…